Omeros (NASDAQ:OMER) Shares Down 6.5% – Here’s What Happened

Omeros Corporation (NASDAQ:OMER)’s stock price dropped 6.5% during mid-day trading on Thursday . The stock traded as low as $11.54 and last traded at $11.2970. Approximately 141,864 shares were traded during mid-day trading, a decline of 91% from the average daily volume of 1,501,906 shares. The stock had previously closed at $12.08.

Omeros News Roundup

Here are the key news stories impacting Omeros this week:

• Positive Sentiment: Q4 results and one‑time windfall: Omeros reported strong Q4 results (net income of $86.5M, $1.22/sh) driven in part by a deal with Novo Nordisk that materially boosted quarterly earnings—a major catalyst for upside in the quarter. BusinessWire: Omeros Reports Q4 and Year‑End 2025 Results
• Positive Sentiment: Commercial outlook — YARTEMLEA funding and cash targets: Management says YARTEMLEA is expected to be financially self‑sustaining in 2026 and targets positive company cash flow in 2027, which reduces near‑term financing risk and supports longer‑term upside. Seeking Alpha: Omeros Expects YARTEMLEA to Be Self‑Sustaining
• Positive Sentiment: Investor speculation / flow: Unusually large call buying was reported (7,487 calls), indicating speculative bullish positioning that can amplify intraday moves on further news. (reported market activity)
• Neutral Sentiment: Bull‑case commentary ahead of Q1 commercial updates: Analysts and commentators are laying out bullish scenarios tied to upcoming Q1 commercial metrics and launch execution; useful for traders positioning into updates. Seeking Alpha: Making The Bull Case
• Neutral Sentiment: Analyst commentary roundup: Coverage pieces (Globe and Mail) and multiple earnings‑call transcripts provide analyst viewpoints and detail on commercialization progress — helpful for modeling but not a single definitive catalyst. Globe and Mail: Analysts Offer Insights on OMER
• Neutral Sentiment: Earnings call details available: Full Q4 2025 call transcripts and summaries (Seeking Alpha, InsiderMonkey, Yahoo Finance) reveal management commentary and questions on commercial traction and margin outlook — read for specifics that could inform near‑term guidance changes. Seeking Alpha: Q4 2025 Earnings Call Transcript
• Negative Sentiment: Market reaction / profit taking: Despite the positive earnings and guidance items, the stock is trading lower today — likely profit‑taking after the after‑hours pop and/or positioning ahead of upcoming Q1 commercial metrics. MSN: OMER Stock Surges After Hours on Novo Deal
• Negative Sentiment: Ongoing earnings uncertainty: Some analyst models still forecast a negative EPS for the current fiscal year (consensus cited ~‑3.09), so longer‑term profitability and execution risk remain material for valuation. (consensus estimates)

Analyst Ratings Changes

A number of research analysts recently weighed in on the company. HC Wainwright boosted their target price on Omeros from $20.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday, January 8th. D. Boral Capital reaffirmed a “buy” rating and set a $36.00 price target on shares of Omeros in a report on Tuesday, January 27th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Omeros in a report on Thursday, January 22nd. Finally, Wall Street Zen lowered shares of Omeros from a “hold” rating to a “sell” rating in a research report on Saturday, January 10th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $40.33.

Omeros Trading Down 7.2%

The stock has a market cap of $794.72 million, a P/E ratio of -22.38 and a beta of 2.53. The firm has a 50-day simple moving average of $11.40 and a two-hundred day simple moving average of $9.78.

Omeros (NASDAQ:OMER) last announced its earnings results on Tuesday, March 31st. The biopharmaceutical company reported $3.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.55) by $3.69. Sell-side analysts predict that Omeros Corporation will post -3.09 earnings per share for the current year.

Insider Transactions at Omeros

In other Omeros news, CAO David J. Borges sold 30,000 shares of the business’s stock in a transaction dated Tuesday, January 13th. The shares were sold at an average price of $12.31, for a total value of $369,300.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 12.90% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Omeros

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Newbridge Financial Services Group Inc. acquired a new position in Omeros in the second quarter valued at about $280,000. Intech Investment Management LLC grew its stake in Omeros by 28.4% during the second quarter. Intech Investment Management LLC now owns 34,108 shares of the biopharmaceutical company’s stock worth $102,000 after buying an additional 7,538 shares in the last quarter. Avantax Planning Partners Inc. increased its holdings in Omeros by 30.7% in the 4th quarter. Avantax Planning Partners Inc. now owns 13,200 shares of the biopharmaceutical company’s stock valued at $227,000 after buying an additional 3,100 shares during the period. Comerica Bank increased its holdings in Omeros by 8.6% in the 4th quarter. Comerica Bank now owns 38,000 shares of the biopharmaceutical company’s stock valued at $653,000 after buying an additional 3,000 shares during the period. Finally, UBS Group AG raised its position in shares of Omeros by 213.5% in the 4th quarter. UBS Group AG now owns 2,222,982 shares of the biopharmaceutical company’s stock valued at $38,180,000 after buying an additional 1,513,893 shares in the last quarter. 48.79% of the stock is currently owned by institutional investors and hedge funds.

About Omeros

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.